An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.
The drug’s actions, observed in isolated human cells in one trial and in rodents in the other, are especially encouraging because they attacked not only the bulk of the tumor cells but also the rare cancer stem cells that are believed to be responsible for most of a cancer’s growth, said Dr. Jerry Shay, professor of cell biology and a senior co-author of both papers. The
After extensively using stem cell therapy for treatment of leukemia, doctors are now pushing for using it to help cure solid tumours.
Doctors from various countries have congregated in the city to deliberate on the efficacy of using stem cells to treat the side-effects of chemotherapy, which, if given in high dosage, kills healthy cells as well.
“In several patients we have observed that the white blood cell count plummets following chemotherapy. This brings down the person’s resistance to infections. By transplanting stem cells we could counter that,” said Dr Ranjan Kumar Mohapatra, oncologist at Global Cancer Institute which is organising
Washington State University researchers provided computer analyses for a new gene therapy study published in Science Translational Medicine.
The study – conducted by the Fred Hutchinson Cancer Research Center in Seattle and published May 9 – found stem cell gene therapy could protect blood cells from damage by chemotherapy in patients suffering from glioblastoma (malignant brain tumors), thereby extending life expectancy.
The WSU laboratory of co-author Grant D. Trobridge, assistant professor of pharmaceutical sciences, developed bioinformatics software that aided the Fred Hutchinson researchers in evaluating the safety of the procedure. The approach was to remove blood stem cells, add a gene
For children born with immunodeficiencies, researchers may have found a better way for them to get the help they need from stem-cell transplants (…)
Children with primary immunodeficiencies have genetic defects in their immune system that leave them open to infection and other complications. Stem-cell transplants can replace the defective immune system with one derived from healthy donor bone marrow, but without a stem-cell transplant, many of these children might die, the researchers noted in a journal news release.
In order to create space for the donor stem cells and prevent rejection, the patient usually undergoes chemotherapy, radiotherapy or both. This
Image via Wikipedia
Italian Welfare Undersecretary Ferruccio Fazio disapproves of private biobanks and is clearly in favor of the “allogenic” conservation of umbilical cord stem cells, meaning the conservation of stem cells saved for the exclusive use of the donor-patient. Speaking about a government report on “the appropriate use of umbilical cord stem cells”, Fazio outlined the government’s approach on the issue. A few weeks after a ministerial decree dictating new regulations for umbilical cord conservation, Fazio explained autologous donation, meaning conservation of stem cells for yourself, “is not only less useful, but also less efficient as